Literature DB >> 24820653

Association between alendronate, serum alkaline phosphatase level, and heterotopic ossification in individuals with spinal cord injury.

Avraam Ploumis, Jayne M Donovan, Mobolaji O Olurinde, Dana M Clark, Jason C Wu, Douglas J Sohn, Kevin C O'Connor.   

Abstract

CONTEXT/
OBJECTIVE: Only sparse evidence exists regarding the effectiveness of oral alendronate (ALN) in the prevention of heterotopic ossification (HO) in patients with spinal cord injury (SCI). The objective of this study is to investigate the protective effect of oral ALN intake on the appearance of HO in patients with SCI. STUDY
DESIGN: Retrospective database review.
SETTING: A Spinal Cord Unit at a Rehabilitation Hospital. PARTICIPANTS: Two hundred and ninety-nine patients with SCI during acute inpatient rehabilitation.
INTERVENTIONS: Administration of oral ALN. OUTCOME MEASURES: The incidence of HO during rehabilitation was compared between patients with SCI receiving oral ALN (n = 125) and patients with SCI not receiving oral ALN (n = 174). The association between HO and/or ALN intake with HO risk factors and biochemical markers of bone metabolism were also explored.
RESULTS: HO developed in 19 male patients (6.35%), however there was no significant difference in the incidence of HO in patients receiving oral ALN or not. The mean odds ratio of not developing versus developing HO given ALN exposure was 0.8. Significant correlation was found between abnormal serum alkaline phosphatase (ALP) levels and HO appearance (P < 0.001) as well as normal serum ALP and ALN intake (P < 0.05).
CONCLUSION: Even though there was no direct prevention of HO in patients with SCI by oral ALN intake, abnormal serum ALP was found more frequently in patients with HO development and without oral ALN intake. This evidence could suggest that ALN may play a role in preventing HO, especially in patients with acute SCI with increasing levels of serum ALP.

Entities:  

Keywords:  Alendronate; Heterotopic ossification; Spinal cord injury

Mesh:

Substances:

Year:  2014        PMID: 24820653      PMCID: PMC4397201          DOI: 10.1179/2045772314Y.0000000213

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  35 in total

1.  The effect of etidronate on late development of heterotopic ossification after spinal cord injury.

Authors:  K Banovac
Journal:  J Spinal Cord Med       Date:  2000       Impact factor: 1.985

Review 2.  Neurogenic heterotopic ossification in spinal cord injury.

Authors:  A A van Kuijk; A C H Geurts; H J M van Kuppevelt
Journal:  Spinal Cord       Date:  2002-07       Impact factor: 2.772

Review 3.  Prevention and treatment of heterotopic ossification after spinal cord injury.

Authors:  Kresimir Banovac; Andrew L Sherman; Irene M Estores; Filip Banovac
Journal:  J Spinal Cord Med       Date:  2004       Impact factor: 1.985

4.  Prevention of heterotopic ossification after spinal cord injury with indomethacin.

Authors:  K Banovac; J M Williams; L D Patrick; Y M Haniff
Journal:  Spinal Cord       Date:  2001-07       Impact factor: 2.772

Review 5.  The effect of nonsteroidal anti-inflammatory drug administration on acute phase fracture-healing: a review.

Authors:  Andrew P Kurmis; Timothy P Kurmis; Justin X O'Brien; Tore Dalén
Journal:  J Bone Joint Surg Am       Date:  2012-05-02       Impact factor: 5.284

Review 6.  Approach to a patient with elevated serum alkaline phosphatase.

Authors:  Asma Siddique; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2012-04-06       Impact factor: 6.126

7.  The influence of alendronate on bone formation and resorption in a rat ectopic bone development model.

Authors:  Avinoam Yaffe; Ron Kollerman; Hila Bahar; Itzhak Binderman
Journal:  J Periodontol       Date:  2003-01       Impact factor: 6.993

8.  Myositis ossificans circumscripta of the knee improved by alendronate.

Authors:  Kaouther Saadallaoui Ben Hamida; R Hajri; H Kedadi; H Bouhaouala; M Hadj Salah; A Mestiri; L Zakraoui; M H Doughi
Journal:  Joint Bone Spine       Date:  2004-03       Impact factor: 4.929

9.  Prevention of bone loss in paraplegics over 2 years with alendronate.

Authors:  Yvonne Zehnder; Simone Risi; Dieter Michel; Hans Knecht; Romain Perrelet; Marius Kraenzlin; Guido A Zäch; Kurt Lippuner
Journal:  J Bone Miner Res       Date:  2004-03-22       Impact factor: 6.741

10.  The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury.

Authors:  Rajendra S Singh; Michael C Craig; Charles R Katholi; Amie B Jackson; James M Mountz
Journal:  Arch Phys Med Rehabil       Date:  2003-11       Impact factor: 3.966

View more
  5 in total

1.  Treatments that are perceived to be helpful for non-neuropathic pain after traumatic spinal cord injury: a multicenter cross-sectional survey.

Authors:  Chung-Ying Tsai; Thomas N Bryce; Andrew D Delgado; Sara Mulroy; Bria Maclntyre; Susan Charlifue; Elizabeth R Felix
Journal:  Spinal Cord       Date:  2021-03-19       Impact factor: 2.772

2.  The Time-Dependent Role of Bisphosphonates on Atherosclerotic Plaque Calcification.

Authors:  Amirala Bakhshian Nik; Hooi Hooi Ng; Manuel Garcia Russo; Francesco Iacoviello; Paul R Shearing; Sergio Bertazzo; Joshua D Hutcheson
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-25

Review 3.  The hypoxic microenvironment: a driving force for heterotopic ossification progression.

Authors:  Yifei Huang; Xinyi Wang; Hui Lin
Journal:  Cell Commun Signal       Date:  2020-02-07       Impact factor: 5.712

4.  A Preliminary Cohort Study Assessing Routine Blood Analyte Levels and Neurological Outcome after Spinal Cord Injury.

Authors:  Sharon J Brown; Gabriel M B Harrington; Charlotte H Hulme; Rachel Morris; Anna Bennett; Wai-Hung Tsang; Aheed Osman; Joy Chowdhury; Naveen Kumar; Karina T Wright
Journal:  J Neurotrauma       Date:  2019-08-06       Impact factor: 5.269

Review 5.  Effectiveness of Prophylactic Interventions in Neurogenic Heterotopic Ossification (NHO): A Systematic Review.

Authors:  Syed Muhammad Hannan Ali Rizvi; Joudi Sharaf; Kerry-Ann D Williams; Maha Tariq; Maitri V Acharekar; Sara Elena Guerrero Saldivia; Sumedha Unnikrishnan; Yeny Y Chavarria; Adebisi O Akindele; Ana P Jalkh; Aziza K Eastmond; Chaitra Shetty; Lubna Mohammed
Journal:  Cureus       Date:  2022-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.